Fentanyl Test Strips for Pharmacies & Retail

One of the more surprising findings from recent research is the relative absence of specific pharmacy board regulations governing the sale and distribution of fentanyl test strips. A 2025 implementation study focused on Pennsylvania community pharmacies noted that there are currently no specific regulations on how drug checking test strips can be provided through community pharmacies in that state, and this regulatory gap appears common across most jurisdictions. Unlike naloxone, which in many states requires standing orders or pharmacist protocols for over-the-counter dispensing, fentanyl test strips generally do not require a prescription, a pharmacist consultation, or any special dispensing procedures. They are treated as general consumer health products.

Independent pharmacies are uniquely positioned to lead in FTS distribution due to their community ties, operational flexibility, and the trust they have built with local populations. Research published in the Journal of the American Pharmacists Association found that independent pharmacy owners have greater autonomy over product stocking decisions compared to their counterparts at chain pharmacies, where corporate purchasing policies may create bottlenecks. A 2023 survey of North Carolina pharmacists found that 79.3% of the 592 respondents were somewhat or very willing to sell fentanyl test strips, with 86.9% willing to refer patients to harm reduction organizations and 81.9% willing to counsel customers on FTS use. Community Pharmacy in Madison, Wisconsin provides a real-world model: the independent pharmacy partnered with Public Health Madison and Dane County to distribute free fentanyl testing strips alongside clean needle and syringe kits and Narcan.

Where fentanyl test strips are placed within a pharmacy has significant implications for accessibility, destigmatization, and sales volume. Current best practice, informed by the CVS model and harm reduction expert recommendations, is to position FTS in the same aisle as other home health testing products such as pregnancy tests, COVID rapid tests, blood pressure monitors, and urinalysis strips. This placement normalizes the product, frames it as a routine health and safety tool, and reduces the stigma a customer might feel when purchasing it. Placing FTS behind the pharmacy counter or in a locked case, while sometimes done for loss prevention, can create barriers that deter purchase and reinforce the perception that these are shameful products. An alternative approach used by some pharmacies is to display FTS near the naloxone (Narcan) section, creating a dedicated harm reduction zone that signals the pharmacy\\

Stigma remains one of the most significant barriers to FTS access in pharmacy settings. A Health Affairs analysis noted that the pervasive stigma surrounding people who use drugs creates barriers around FTS and other harm reduction tools, with stigma and access bidirectionally affecting one another: stigma limits access to harm reduction, while expanding access can gradually reduce stigma. Research has documented that people who use drugs report reluctance to engage with harm reduction services at distribution sites or points of care due to fear of legal repercussions and experiences of judgment. Pharmacies can actively combat stigma through several strategies. First, staff training should include modules on nonjudgmental communication, person-first language (saying \\

Pharmacies have multiple channels for sourcing fentanyl test strips at wholesale pricing. Standard retail pricing for FTS ranges from $1 to $2 per strip at the consumer level, while wholesale pricing varies significantly by volume and supplier. Products like the Subcheck SC-1 are available at approximately $0.20 per strip with a complete kit (strip, scoop, water vessel, instructions included), making them the most cost-effective option for pharmacies looking to maximize margins or offer the lowest consumer price point.

Although insurance and Medicaid do not currently cover fentanyl test strips as a reimbursable product, and FTS cannot be prescribed, multiple funding streams exist that pharmacies can use. In April 2021, SAMHSA and the CDC jointly authorized the use of federal grant funds to purchase FTS, applicable to programs including SAMHSA\\

The fentanyl test strip market is evolving rapidly, with new products and features designed specifically for retail consumer use. Multiple brands compete in the U.S. market, with products ranging from basic strip-only packages to complete kits with accessories. A 2025 usability study published in Substance Use & Misuse compared five FTS brands distributed by U.S.

For pharmacy owners and managers ready to begin stocking fentanyl test strips, the following evidence-based implementation roadmap draws on published research and successful program models. Step one: select a wholesale supplier and product, considering unit cost, shelf life, packaging quality, and included consumer education materials; products like the Subcheck SC-1 offer the most competitive wholesale pricing at approximately $0.20 per strip. Step two: train all pharmacy staff, including pharmacists, pharmacy technicians, and front-of-store associates, using available training resources from the National Harm Reduction Coalition, the CDC\\